TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05188170
Drug: Niclosamide
Normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Niclosamide will be administered orally for 14 days. Each dose will be followed by backbone chemotherapy
Study: NCT05456542
Drug: Dexamethasone 4mg
Normalized name: DEXAMETHASONE 4MG TAB
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone, will be administered to those patients who fail the CLT in the intervention arm (4mg intravenous every 6 hours for 12-24 hours). Dexamethasone belongs to a class of drugs known as corticosteroids
Study: NCT06186700
Drug: Pentoxifylline 400mg plus chemotherapy
Normalized name: pentoxifylline 400 MG
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient will take 400 mg tablets of Pentoxifylline, 3 tablets per day, starting from the first day of the first cycle of doxorubicin/cyclophosphamide till finishing the cycles of neoadjuvant chemotherapy comprised intravenous Doxorubicin 60 mg/m²/cycle with intravenous Cyclophosphamide 600 mg/m²/cycle for four cycles, followed by weekly paclitaxel or dose-dense paclitaxel.
Study: NCT05293028
Drug: F527
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.001、0.01、0.1、0.3、1、3 and10 mg/kg QW
Study: NCT05761301
Drug: ALN-KHK
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN-KHK will be administered by subcutaneous (SC) injection.
Study: NCT05943665
Drug: MDMA
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: medication and therapy combined
Study: NCT04903678
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan is performed for intrathecal chemotherapy
Study: NCT04735393
Drug: Reproxalap Ophthalmic Solution (0.25%)
Normalized name: Reproxalap
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reproxalap Ophthalmic Solution (0.25%) administered for six weeks (QID for four weeks then BID for two weeks).
Study: NCT04735393
Drug: Reproxalap Ophthalmic Solution (0.25%)
Normalized name: Reproxalap
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reproxalap Ophthalmic Solution (0.25%) administered for one year (QID for four weeks then BID for 11 months).
Study: NCT06238622
Drug: BI 1015550
Normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1015550
Study: NCT05218889
Drug: surufatinib + camrelizumab + nab-paclitaxel + S-1
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: phase 1b: surufatinib 200 or 250 mg/d, qd po; camrelizumab: 200mg, I.V., D1, Q3W; nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; S-1: 40mg bid, D1-14, Q3W; DLTs will be evaluated at first cycle;~phase 2: surufatinib RP2D + camrelizumab + nab-paclitaxel + S-1 when evaluated SD, PR or CR after 4-6 cycles (according to RECIST 1.1), followed by maintenance treatment: surufatinib + camrelizumab + S-1
Study: NCT05218889
Drug: nab-paclitaxel + gemcitabine
Normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W
Study: NCT06035874
Drug: Bempedoic acid
Normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patient willl be randomized 1:1 in both the arms
Study: NCT06140524
Drug: Linvoseltamab
Normalized name: Linvoseltamab
DrugBank: Linvoseltamab (DB17447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous (IV) infusion
Study: NCT05852431
Drug: Pegozafermin
Normalized name: Pegozafermin
DrugBank: Pegozafermin (DB19062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT05998395
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib at 5 mg twice a day (BID) for 1 week and then at 10 mg BID for 13-73 weeks and 1 week of 5 mg BID before stopping ruxolitinib.
Study: NCT05749822
Drug: Fenofibrate 200mg
Normalized name: FENOFIBRATE 200MG CAP
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate 200mg/day
Study: NCT05749822
Drug: UDCA
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 13-15mg/kg/day
Study: NCT05016349
Drug: All trans-retinoic acid
Normalized name: all trans-Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
Study: NCT05016349
Drug: 13-Cis Retinoic Acid plus Tocopherol
Normalized name: 13-cis-retinoic acid
DrugBank: Tocopherol (DB11251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-Cis Retinoic Acid (50 mg/m2/d) Tocopherol (800 mg/day) supplied orally at the total dosage of 50 mg/m2/d (two daily administrations of 25 mg/m2 each). Treatment will last 28 days
Study: NCT05016349
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mifepristone 200mg capsules daily for 28 days
Study: NCT05016349
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Liquid taken orally for daily for 28 days
Study: NCT05016349
Drug: 9 cis retinoic acid
Normalized name: 9-cis-retinoic acid
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9 cis retinoic acid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
Study: NCT05016349
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be given 10mg Tamoxifen twice a day. Treatment will last 28 days
Study: NCT04862377
Drug: Poractant Alfa Intratracheal Suspension [Curosurf]
Normalized name: poractant alfa Intratracheal Suspension [Curosurf]
DrugBank: Poractant alfa (DB09113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Poractant alfa (Curosurf®):~First dose of treatment: 200mg/Kg. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg.
Study: NCT04862377
Drug: Budesonide 0.5 MG/ML
Normalized name: budesonide 0.5 MG/ML
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Poractant alfa (Curosurf®) + Budesonide nebulizer solution (Budesonida Aldo-Unión 0.5mg/mL suspensión para inhalación por nebulizador®):~First dose: 200mg/Kg of surfactant + 0.25mg/Kg of budesonide. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg of surfactant + 0.25mg/Kg of budesonide.
Study: NCT05680818
Drug: Encaleret
Normalized name: Encaleret
DrugBank: Encaleret (DB18096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as film-coated tablet for oral use
Study: NCT04816097
Drug: Dexamethasone phosphate
Normalized name: Dexamethasone Phosphate
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 doses of dexamethasone 6mg IM 48h before elective CS.
Study: NCT00005017
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00005017
Drug: Abacavir sulfate
Normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00005017
Drug: Amprenavir
Normalized name: Amprenavir
DrugBank: Amprenavir (DB00701)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00005017
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005017
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00005017
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05034562
Drug: Gallium Ga 68-labeled PSMA-11
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium nitrate (DB05260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00000654
Drug: Fialuridine
Normalized name: Fialuridine
DrugBank: Fialuridine (DB15427)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04663126
Drug: Tc-99m tilmanocept
Normalized name: TECHNETIUM TC-99M TILMANOCEPT
DrugBank: Technetium Tc-99m tilmanocept (DB09266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV 250 µg Tilmanocept, labelled with 370 MBq of Tc-99m
Study: NCT04582266
Drug: Remdesivir
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RDV was not provided as part of the study. Participants were administered RDV intravenously once daily for up to 10 days per clinical care.
Study: NCT05322733
Drug: Orelabrutinib
Normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg capsules administered orally once daily (28-day cycles). Until 12 or 24 cycles and following BM undetectable MRD, or disease progression, or intolerant toxicity.
Study: NCT05322733
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1000 mg administered intravenously once on Day 1, 8, 15 of first cycle and on Day 1 of following cycles for maximal 12 cycles (28-day cycles).
Study: NCT06239467
Drug: OKI-219
Normalized name: OKI-179
DrugBank: OKI-179 (DB17583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral twice daily
Study: NCT06239467
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intramuscular injection
Study: NCT06239467
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV)
Study: NCT05322733
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
Study: NCT05430152
Drug: Low-Dose Naltrexone
Normalized name: ethinyl estradiol
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study drug dosing schedule (LDN):~* Week 1: 1 mg/day (1 mg cap)~* Week 2: 2 mg/day (two 1 mg caps)~* Week 3: 3 mg/day (three 1mg caps)~* Weeks 4-6: 4.5 mg/day (three 1 mg caps, plus one 1.5 mg cap = 4.5 mg/day)~* Weeks 7-16: 4.5 mg/day (one 4.5 mg cap) OR based on self-titration dosage (one 1mg, 2mg, or 3mg cap)
Study: NCT05485779
Drug: AQ280
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose form: capsule, hard~Strength: 3 to 100 mg~Method of administration: oral
Study: NCT04695080
Drug: Cladribine (MAVENCLAD®)
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine (MAVENCLAD®) 3.5mg/kg, administered as weight-adjusted 10mg tablets in two treatment courses (12 months apart) lasting 8- 10 days each.~Cladribine (MAVENCLAD®) 10mg available in blister packs of 1 tablet, 4 tablets and 6 tablets.
Study: NCT05583552
Drug: Imetelstat sodium
Normalized name: imetelstat sodium
DrugBank: Imetelstat (DB14909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection
Study: NCT06087588
Drug: 0.9%sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PENG sham block with 20ml 0,9% normal saline
Study: NCT06087588
Drug: 95% ethanol
Normalized name: ALCOHOL 95 mL in 100 mL TOPICAL SOLUTION [95% Ethanol (190 Proof)]
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PENG neurolysis with 2.5ml of 95% ethanol
Study: NCT06342986
Drug: FT536
Normalized name: Fluticasone Terephthalate 536
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FT536 is an allogeneic natural killer (NK)-cell immunotherapy produced from a clonal master humaninduced pluripotent stem cell (iPSC) line.
Study: NCT06342986
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 25 mg/m2 IV given on day -5. Given consecutively with CY.
Study: NCT05965193
Drug: Intravenous thrombolysis(rt-PA)
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% dose of rt-PA (0.9 mg/kg) is given as bolus and the rest given as an infusion over the remaining 1 hour. Maximum dose 90mg.
Study: NCT05253131
Drug: Selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Selumetinib (AZD6244) is an oral selective inhibitor of the mitogen-activated protein kinase kinase (MEK) 1/2 currently in development for adult malignancies, pediatric low grade gliomas, and NF1-associated plexiform neurofibromas.~* BI is a potent and selective inhibitor of BRD4/BET bromodomain currently in development for adult malignancies.~* Durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that is currently indicated for patients with advanced urothelial carcinoma and unresectable non-small cell lung cancer.
Study: NCT05170256
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Addition of trastuzumab to standard treatment (fluoropyrimidine/platinum doublet with pembrolizumab)
Study: NCT06232694
Drug: Venetoclax : 100mg on day 1, 200mg on day 2, 400mg on days 3 to 8; oral administration;
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction Phase Regimen
Study: NCT06232694
Drug: Venetoclax (Venetoclax): 400mg on day 1 to day 7; oral administration;
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Consolidation therapy after remission
Study: NCT04610970
Drug: TQ-B3525 tablets
Normalized name: TQS-168
DrugBank: TQS-168 (DB18108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
Study: NCT02211222
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib at starting doses of 24-mg, 20-mg, or 14-mg will be administered as a combination of 10-mg capsules and 4-mg capsules to be taken once a day (QD) (recommended to be taken the same time each day). Subjects will receive one of three starting doses of lenvatinib, 24-mg/day, 20-mg/day, or 14-mg/day. Dose reductions occur in succession based on the previous dose level (24, 20, 14, and 10 mg/day). Any dose reduction below 10 mg/day must be discussed with the sponsor. Once the dose has been reduced, it cannot be increased at a later date.
Study: NCT00000702
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02925520
Drug: Omegaven
Normalized name: Omegaven
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy with Omegaven will be provided at a dose of 1 gm/kg/day infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Parenteral fat emulsion (Intralipid) will be administered only if necessary to administer adequate calories during Omegaven therapy. The same standards of care provided to all patients receiving parenteral nutrition solution will be followed.~Home Use of Omegaven:~The Omegaven dose for home use will be the same as that used while in the hospital: 1 gm/kg/day. As with the inpatient part of the protocol, this is a maximum dose and may be decreased at the discretion of the provider.
Study: NCT06120491
Drug: Saruparib
Normalized name: Saruparib
DrugBank: Saruparib (DB18982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT06120491
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral
Study: NCT06120491
Drug: Darolutamide
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral
Study: NCT06120491
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral
Study: NCT05424757
Drug: PEG 3350
Normalized name: PEG 3350
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data and biospecimens will be collected from two groups of children:~* Children who have taken PEG 3350 daily for at least 30 days.~* Children who have NOT taken PEG 3350 for at least 30 days.~No changes to medicines are recommended as part of this study.
Study: NCT04793867
Drug: Xenon
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be scanned on a commercial 3T whole-body MRI scanner equipped with high-performance gradient systems. Natural isotopic abundance or isotopically-enriched xenon gas (\~86% 129Xe, Linde Inc.) will be used for all studies. Subjects will be positioned supine in the scanner with a 129Xe RF coil around their chests. Using conventional proton MRI and a breath-hold acquisition, scout images will be obtained to localize the subject for subsequent 129Xe acquisitions. 129Xe images will be acquired using the same breath-hold maneuver and a pulse sequence, covering the entire lung (acquisition time \<10 s, approximately 3-mm in-plane resolution, 15-mm slice thickness or less). Additional scans (sequences) may be performed. A maximum of 4 doses of 129Xe will be given throughout the study following the calibration dose.
Study: NCT05664113
Drug: Fecal microbiota transplant (FMT)
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMT Lower Delivery Microbiota Preparation, Dose: 250 mL of Microbiota Preparation Material and Route of administration: colonoscopy FMT Upper Delivery Microbiota Preparation, Dose: 60 mL of Microbiota Preparation Material and Route of administration: Naso-enteral tube
Study: NCT03753204
Drug: Furosemide 40 mg
Normalized name: furosemide 40 MG
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blood pressure data from the monitors will be downloaded and the average of the systolic blood pressure of the day of salt loading, from 12 noon (end of the saline infusion) until 10 pm will be used as the BP for the salt-loading period of study. The average of the systolic blood pressure of the day of salt depletion, from 12 noon (second dose of furosemide) until 10 pm will be used as the BP for the salt-depleted period of study. A fall in systolic BP ≥10 mm Hg from the salt-loading to the salt-depletion periods will be used to classify a subject as salt sensitive.
Study: NCT06411249
Drug: Belimumab (GSK1550188)
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: GSK1550188 will be administered subcutaneously.
Study: NCT05741060
Drug: S-equol
Normalized name: S-equol
DrugBank: Equol (DB11674)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental drug
Study: NCT06680882
Drug: prucapride
Normalized name: prucalopride
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: was administered prucapride as a monotherapy
Study: NCT03937830
Drug: durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1,150 mg flat dose every 21 days, starting on day 1 of cycle 1
Study: NCT05047185
Drug: Deucrictibant low dose
Normalized name: ethinyl estradiol
DrugBank: Deucrictibant (DB18303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deucrictibant softgel capsules for oral use (PHVS416)
Study: NCT05047185
Drug: Deucrictibant high dose
Normalized name: high-density polyethylene
DrugBank: Deucrictibant (DB18303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deucrictibant softgel capsules for oral use (PHVS416)
Study: NCT03937830
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7.5 mg/kg dose every 21 days, starting on day 1 of cycle 2
Study: NCT03937830
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300, 150 or 75 mg once on day 1 of cycle 1
Study: NCT03814109
Drug: Levamlodipine 2.5/ 5 mg
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet, oral, once a day.
Study: NCT06528483
Drug: Sacituzumab Govitecan + Zimberelimab
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab Govitecan 7.5 mg/kg IV for 3 cycles Zimberelimab 360 mg IV for 16 cycles~Patients will be treated with Sacituzumab Govitecan 1,8q21 plus + Zimberelimab q21 for 3 cycles then radiological imaging and TURB will be repeated and patients with Stability of disease or down staging will continue Zimberelimab until disease progression, or unacceptable toxicities or completion of treatment (16 cycles). Patients with progressive disease after 3 cycles of study intervention will be treated as per clinical practice.
Study: NCT05777993
Drug: Mitapivat
Normalized name: Mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets
Study: NCT05167487
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
Study: NCT05167487
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
Study: NCT05257993
Drug: Gemcitabine-nab-paclitaxel
Normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * After IV administration of nab-paclitaxel 125 mg/m2 for 30 minutes~* IV administration of Gemcitabine 1000 mg/m2 for 30 minutes~* Administration on Days 1, 8, and 15 on a 28-day cycle
Study: NCT06247787
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Receive IV and IT
Study: NCT06247787
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive IV
Study: NCT06417190
Drug: Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-arm, open-label
Study: NCT05446870
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle
Study: NCT05446870
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5 to 6 by IV infusion on Day 1 of each 21-day cycle